|
Klein, Cheri Enders; Gupta, Elora; Reid, Joel M et al. (2002) Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide. Clin Pharmacol Ther 72:638-47
|
|
Gordon, E J; Daugherty, C K (2001) Referral and decision making among advanced cancer patients participating in Phase I trials at a single institution. J Clin Ethics 12:31-8
|
|
Mani, S; Kugler, J W; Sciortino, D F et al. (1998) Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: a University of Chicago phase II consortium study. Ann Oncol 9:1035-7
|
|
Mani, S; Kugler, J W; Knost, J A et al. (1998) Phase II trial of 150-minute weekly infusion of gemcitabine in advanced colorectal cancer: minimal activity in colorectal cancer. Invest New Drugs 16:275-8
|
|
Vogelzang, N J; Mani, S; Schilsky, R L et al. (1998) Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. Clin Cancer Res 4:929-34
|
|
Gupta, E; Mick, R; Ramirez, J et al. (1997) Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 15:1502-10
|
|
Daugherty, C K; Siegler, M; Ratain, M J et al. (1997) Learning from our patients: one participant's impact on clinical trial research and informed consent. Ann Intern Med 126:892-7
|
|
Soliven, B; Dhand, U K; Kobayashi, K et al. (1997) Evaluation of neuropathy in patients on suramin treatment. Muscle Nerve 20:83-91
|
|
Ratain, M J; Mick, R; Janisch, L et al. (1996) Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics 6:93-101
|
|
Kobayashi, K; Weiss, R E; Vogelzang, N J et al. (1996) Mineralocorticoid insufficiency due to suramin therapy. Cancer 78:2411-20
|
Showing the most recent 10 out of 22 publications
